An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

Summary

The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease.

Timeline

Start

2007-02

Primary completion

2008-09

Completion

2008-09

Outcome

Met primary endpoint

registry Placebo Group vs Galantamine Group 1; p = 0.0113; Mean Difference (Final Values) -1.49 (95% CI -2.64 to -0.34) NCT00814801 ↗

registry Placebo Group vs Galantamine Group 2; p <0.0001; Mean Difference (Final Values) -2.59 (95% CI -3.74 to -1.44) NCT00814801 ↗

Publications

• Lim AWY, Schneider L, Loy C. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Galantamine	Small molecule	16 mg	Oral
Subject	Galantamine	Small molecule	24 mg	Oral

Indications